CN102355897B - 用作药物的顺式单不饱和脂肪酸的α-衍生物 - Google Patents

用作药物的顺式单不饱和脂肪酸的α-衍生物 Download PDF

Info

Publication number
CN102355897B
CN102355897B CN200980156029.6A CN200980156029A CN102355897B CN 102355897 B CN102355897 B CN 102355897B CN 200980156029 A CN200980156029 A CN 200980156029A CN 102355897 B CN102355897 B CN 102355897B
Authority
CN
China
Prior art keywords
cis
fatty acids
compound
formula
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN200980156029.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN102355897A (zh
Inventor
帕布洛·维森特·埃斯克里巴鲁伊斯
赛维尔·巴斯奎特斯邹贝特
格温多琳·巴塞罗科比利基
维多利亚·拉都卡内拉斯
拉斐尔·阿尔瓦莱斯马蒂内丝
西尔维娅·泰瑞斯吉梅奈兹
丹尼尔·洛佩兹
乔安娜·巴塞罗埃斯塔瑞拉斯
朱利安·泰勒格林
吉尔拉多·艾维拉马汀
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitat de les Illes Balears
Original Assignee
Universitat de les Illes Balears
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42242375&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102355897(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Universitat de les Illes Balears filed Critical Universitat de les Illes Balears
Publication of CN102355897A publication Critical patent/CN102355897A/zh
Application granted granted Critical
Publication of CN102355897B publication Critical patent/CN102355897B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
CN200980156029.6A 2008-12-09 2009-12-04 用作药物的顺式单不饱和脂肪酸的α-衍生物 Active CN102355897B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES200803480A ES2342997B1 (es) 2008-12-09 2008-12-09 Alpha derivados de acidos grasos cis-monoinsaturados para ser usados como medicamento.
ESP200803480 2008-12-09
PCT/ES2009/070561 WO2010066931A1 (es) 2008-12-09 2009-12-04 Alfa-derivados de ácidos grasos cis-monoinsaturados para ser usados como medicamento

Publications (2)

Publication Number Publication Date
CN102355897A CN102355897A (zh) 2012-02-15
CN102355897B true CN102355897B (zh) 2014-06-04

Family

ID=42242375

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980156029.6A Active CN102355897B (zh) 2008-12-09 2009-12-04 用作药物的顺式单不饱和脂肪酸的α-衍生物

Country Status (18)

Country Link
US (3) US9000042B2 (https=)
EP (4) EP2842555B1 (https=)
JP (2) JP5711140B2 (https=)
KR (1) KR101683643B1 (https=)
CN (1) CN102355897B (https=)
AU (6) AU2009326993B2 (https=)
BR (1) BRPI0922870A8 (https=)
CA (1) CA2745052C (https=)
DK (3) DK2842556T3 (https=)
ES (5) ES2342997B1 (https=)
HU (2) HUE056170T2 (https=)
IL (1) IL213354A (https=)
MX (1) MX2011005978A (https=)
PL (3) PL3366285T3 (https=)
PT (4) PT2374453E (https=)
RU (1) RU2531353C2 (https=)
SI (1) SI3366285T1 (https=)
WO (1) WO2010066931A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2342997B1 (es) 2008-12-09 2011-06-06 Universitat De Les Illes Balears Alpha derivados de acidos grasos cis-monoinsaturados para ser usados como medicamento.
WO2011089265A1 (en) * 2010-01-25 2011-07-28 Bridge Bioresearch Plc Use of fatty acid compounds for lowering blood glucose levels
ES2401629B1 (es) * 2011-10-07 2014-03-04 Universitat De Les Illes Balears Enantiómeros de 2-hidroxiderivados de ácidos grasos y su uso como medicamentos.
WO2013132092A1 (en) * 2012-03-09 2013-09-12 Pensieve International Plc Use of monounsaturated fatty acid compounds for controlling the body weight of a dog or a cat
WO2016062746A1 (en) * 2014-10-21 2016-04-28 Universitat De Les Illes Balears Method for the synthesis of hydroxy-triglycerides and uses thereof for the prevention and treatment of diseases
WO2019099664A1 (en) * 2017-11-16 2019-05-23 The Research Foundation For The State University Of New York Use of 2-hydroxyoleic acid for the treatment of systemic lupus erythematosus and other immune pathologies
CN115052852A (zh) * 2020-01-29 2022-09-13 巴利阿里群岛大学 α-羟基化脂肪酸代谢产物、其医学用途以及作为生物标志物的用途
ES2911474B2 (es) * 2020-11-17 2023-02-06 Univ Illes Balears Profarmacos de acidos grasos monoinsaturados y sus metabolitos: usos medicos y como biomarcadores
US12440467B2 (en) * 2021-12-09 2025-10-14 The Florida International University Board Of Trustees Treatment and prevention of infections using vegetable oil-derived polyols

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1688302A (zh) * 2001-10-11 2005-10-26 巴利阿里群岛大学 羟油酸及相关化合物在制备药物中的应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4928172B1 (https=) * 1969-10-27 1974-07-24
CH558321A (de) * 1971-08-03 1975-01-31 Ciba Geigy Ag Verfahren zur herstellung von carbonsaeuren bezw. carbonsaeuresalzen.
US3931306A (en) * 1973-10-23 1976-01-06 International Flavors & Fragrances Inc. Process for producing isomer mixtures containing high proportions of cis-2-methyl-3-pentenoic acid
DE2448339A1 (de) * 1974-10-10 1976-04-22 Basf Ag Verfahren zur herstellung von olefinisch ungesaettigten carbonsaeureestern
DE2559201B2 (de) * 1975-12-30 1978-06-15 Hoechst Ag, 6000 Frankfurt Organozinnverbindungen und ihre Verwendung als Stabilisatoren
US4241097A (en) * 1979-09-13 1980-12-23 International Flavors & Fragrances Inc. Use of benzodionones in augmenting or enhancing the aroma and taste of a foodstuff
US4391757A (en) * 1981-11-27 1983-07-05 Carstab Corporation Organic antimony containing stabilizer compositions for halogenated polymers
JPS5899432A (ja) * 1981-12-09 1983-06-13 Maruzen Sekiyu Kagaku Kk 不飽和脂肪酸またはその塩およびそれからなる抗菌剤
US4551279A (en) * 1984-01-09 1985-11-05 G. D. Searle & Co. Protease inhibitors
FR2609032B1 (fr) * 1986-12-30 1990-01-05 Centre Nat Rech Scient Epoxydes fonctionnels enantiomeriquement purs, leur procede de preparation et leur application comme synthons chiraux
US4808403A (en) * 1987-03-17 1989-02-28 International Flavors & Fragrances Inc. Use of N,N-diethyl-m-toluamide and/or the ethyl ester of 2-methyl-3-pentenoic acid as insect attractants
US5504107A (en) 1990-01-12 1996-04-02 The Ohio State University Research Foundation Optically pure 4-alkenyl- or 4-alkanyl-2-hydroxytetronic acids and pharmaceutical use thereof
GB9003201D0 (en) * 1990-02-13 1990-04-11 Unilever Plc Cosmetic composition
US5208260A (en) * 1990-03-29 1993-05-04 G. D. Searle & Co. Vinyl Glycine derivatives for memory and learning enhancement or treatment of a cognitive disorder
US5198250A (en) * 1990-07-16 1993-03-30 Lipotech Partners Limited Partnership Food and pharmaceutical compositions containing short chain monounsaturated fatty acids and methods of using
ES2039336T3 (es) * 1991-04-10 1999-08-01 Yu Ruey J Uso de composiciones cosmeticas que contienen acidos 2-hidroxicarboxilicos y compuestos afines para aliviar los indicios de cambios de las uñas.
US6300373B1 (en) 1993-09-10 2001-10-09 American Biogenetic Sciences, Inc. Antiproliferative and neurotrophic molecules
JP3489703B2 (ja) * 1995-10-23 2004-01-26 株式会社ノエビア 微細エマルション組成物
US5856537A (en) * 1996-06-26 1999-01-05 The Scripps Research Institute Inhibitors of oleamide hydrolase
JPH10182338A (ja) * 1996-12-20 1998-07-07 Noevir Co Ltd 水中油型乳化組成物
JP2001523695A (ja) * 1997-11-24 2001-11-27 ザ スクリップス リサーチ インスティテュート ギャップ結合連絡の阻害剤
GB9926833D0 (en) * 1999-11-15 2000-01-12 Univ Sunderland Compositions
GB2385589A (en) * 2000-08-07 2003-08-27 Sofitech Nv Surfactant
US6702756B2 (en) * 2001-12-11 2004-03-09 University Technologies International Inc. Method and apparatus for diagnosing neurological impairment
BR0306957A (pt) 2002-01-22 2004-12-14 Syngenta Participations Ag Herbicidas
US7462349B2 (en) * 2002-10-24 2008-12-09 Nurit Kalderon Beta interferon for the treatment of chronic spinal cord injury
US20040214215A1 (en) * 2003-03-07 2004-10-28 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
EP1622633B1 (en) * 2003-05-15 2016-02-24 Ampio Pharmaceuticals, Inc. Treatment of t-cell mediated diseases
ES2229935B1 (es) * 2003-10-10 2006-10-01 Universitat De Les Illes Balears Utilizacion del acido hidroxioleico y compuestos analagos del mismo como aditivos alimentarios funcionales.
KR100756890B1 (ko) * 2005-08-19 2007-09-07 경희대학교 산학협력단 신경세포 보호활성을 갖는 올레산을 함유하는 조성물
JP2009051732A (ja) * 2005-12-13 2009-03-12 Meiji Seika Kaisha Ltd Ｐｐａｒリガンド活性を有する組成物
WO2009127009A1 (en) 2008-04-18 2009-10-22 Commonwealth Scientific And Industrial Research Organisation Condensation polymers
JP2011516697A (ja) 2008-04-18 2011-05-26 コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガニゼイション ポリウレタン
ES2342997B1 (es) 2008-12-09 2011-06-06 Universitat De Les Illes Balears Alpha derivados de acidos grasos cis-monoinsaturados para ser usados como medicamento.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1688302A (zh) * 2001-10-11 2005-10-26 巴利阿里群岛大学 羟油酸及相关化合物在制备药物中的应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
A Convenient Synthesis of α-Fluoro Carboxylic Acids;Oliver James et al.;《SYNTHESIS》;19940331(第3期);273-275 *
Gas Chromatography/Electron-Capture Negative Ion Mass Spectrometry for the Quantitative Determination of 2- and 3-Hydroxy Fatty Acids in Bovine Milk Fat;RAMONA JENSKE et al.;《J. Agric Food Chem》;20080621;第56卷(第14期);5500-5505 *
Highly Selective Asymmetric Synthesis of 2-Hydroxy Fatty Acid Methyl Esters Through Chiral Oxazolidinone Carboximides;Hong-Sik Hwang et al.;《JAOCS》;20010228;第78卷(第2期);205-211 *

Also Published As

Publication number Publication date
DK2842556T3 (en) 2018-03-26
DK2374453T3 (en) 2015-03-30
MX2011005978A (es) 2011-10-11
US20150297548A1 (en) 2015-10-22
EP2842556A3 (en) 2015-08-05
ES2535498T8 (es) 2016-08-19
CN102355897A (zh) 2012-02-15
US10588883B2 (en) 2020-03-17
JP5711140B2 (ja) 2015-04-30
EP2842556A2 (en) 2015-03-04
IL213354A0 (en) 2011-07-31
AU2018229474B2 (en) 2019-08-22
IL213354A (en) 2017-06-29
EP2842556B1 (en) 2018-01-31
EP2842555A3 (en) 2015-04-15
HUE037396T2 (hu) 2018-08-28
AU2016228167A1 (en) 2016-09-29
WO2010066931A1 (es) 2010-06-17
KR20110126100A (ko) 2011-11-22
US9000042B2 (en) 2015-04-07
AU2018229472B2 (en) 2019-07-18
EP3366285B1 (en) 2021-06-30
WO2010066931A4 (es) 2010-08-05
KR101683643B1 (ko) 2016-12-07
ES2673406T3 (es) 2018-06-21
PT2842555T (pt) 2018-07-06
PL2374453T3 (pl) 2015-07-31
AU2019222955A1 (en) 2019-09-19
HUE056170T2 (hu) 2022-01-28
BRPI0922870A8 (pt) 2017-12-26
EP3366285A1 (en) 2018-08-29
SI3366285T1 (sl) 2021-11-30
ES2342997B1 (es) 2011-06-06
JP2012511510A (ja) 2012-05-24
EP2842555B1 (en) 2018-04-18
AU2016228171A1 (en) 2016-09-29
EP2374453A4 (en) 2012-05-30
DK3366285T3 (da) 2021-10-04
ES2661412T3 (es) 2018-03-28
ES2535498T3 (es) 2015-05-12
ES2899274T3 (es) 2022-03-10
EP2374453B1 (en) 2015-02-18
CA2745052A1 (en) 2010-06-17
US9730906B2 (en) 2017-08-15
AU2018229474A1 (en) 2018-10-04
PL3366285T3 (pl) 2022-01-10
US20180193297A1 (en) 2018-07-12
ES2342997A1 (es) 2010-07-20
BRPI0922870A2 (pt) 2016-01-12
AU2018229472A1 (en) 2018-10-04
AU2009326993B2 (en) 2016-06-16
PT3366285T (pt) 2021-10-07
RU2531353C2 (ru) 2014-10-20
EP2842555A2 (en) 2015-03-04
JP2015061856A (ja) 2015-04-02
PL2842556T3 (pl) 2018-07-31
US20110294883A1 (en) 2011-12-01
AU2009326993A1 (en) 2011-07-07
EP2374453A1 (en) 2011-10-12
CA2745052C (en) 2017-11-07
PT2374453E (pt) 2015-04-28
PT2842556T (pt) 2018-03-19
RU2011128335A (ru) 2013-01-20
AU2019222955B2 (en) 2020-11-05

Similar Documents

Publication Publication Date Title
CN102355897B (zh) 用作药物的顺式单不饱和脂肪酸的α-衍生物
AU2016238970B2 (en) Use of derivatives of polyunsaturated fatty acids as medicaments
HK1232430B (zh) 多不饱和脂肪酸的衍生物作为药物的用途
HK1232207B (zh) 多不饱和脂肪酸的衍生物作为药物的用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant